Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alexandria Real Estate Equities Inc (ARE) vs Johnson & Johnson (JNJ) Price & Performance

Alexandria Real Estate Equities IncTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Alexandria Real Estate Equities Inc vs Johnson & Johnson — how do they compare? Alexandria Real Estate Equities Inc trades at $48.07 (market cap $8.28B), while Johnson & Johnson trades at $260.33 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 75.6× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.

AREJNJ
Market Cap
$8.28B$626.09B
Sector
Real EstateHealth
52-Week High
$87.45$267.24
52-Week Low
$40.41$172.78
Enterprise Value
$20.98B$654.37B
Dividend Yield
5.99%2.06%
Volume
6,156,228

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities (ARE) trades at $48.35, down 2.79% today, with a bearish technical signal and mixed fundamentals. The stock shows a negative net income margin of -37.12% for 2025, though recent Q2 2026 FFO beat estimates. Analyst consensus is a 'Buy' with a $53.71 price target, but technical indicators suggest near-term pressure with support at $47 and resistance at $50.

Outlook remains cautious due to profitability challenges and high debt, but leasing momentum and strategic partnerships offer recovery potential. Risks include ongoing net losses and market volatility, while institutional interest and dividend payments provide some stability. Investors should weigh fundamental weaknesses against long-term real estate sector recovery prospects.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Read more on ARE

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ